Clinical Trial Update: Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression [Phase 1]

View source ↗

Summary

This entry notes the completion of a Phase 1 trial evaluating HPN536 in patients with mesothelin-expressing advanced cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelin-expressing Cancers

Drugs mentioned

• HPN536

Snippet

Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Advanced Cancers Associated With Mesothelin Expression | Phase 1 | Status: COMPLETED